TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15692919

Group type: EXPERIMENTAL
Intervention: Renal doses of dopamine in the postoperative period
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Renal doses of dopamine in the preoperative period
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (100 patients)
Number of subjects: 67
Study: 12495822

Group type: EXPERIMENTAL
Intervention: Intervention group (150 subjects)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (153 subjects)
Number of subjects: 303
Study: 10193730

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 7763202

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (50 mg/kg per day subcutaneously for 12 months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (in subgroup of 81 patients with limb onset)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (in subgroup of 81 patients with limb onset)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (in bulbar subgroup of 29 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (in bulbar subgroup of 29 patients)
Number of subjects: 110
Study: 2187014

Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam
Number of subjects: 152

Group type: COMPARATOR
Intervention: Gentamicin/clindamycin
Number of subjects: 152
Study: 438014

Group type: EXPERIMENTAL
Intervention: Inhalation of dry air at various temperatures (subzero to 80 degrees C) during exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of dry air at temperatures above 37 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of small amounts of water vapor to inspirate at high temperatures
Number of subjects: 0
Study: 30554925

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine periarticular injection (PAI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard-of-care protocol (conventional bupivacaine PAI)
Number of subjects: 59
Study: 28030470

Group type: EXPERIMENTAL
Intervention: Dorsal root ganglion stimulation (DRG)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Dorsal column stimulation (spinal cord stimulation, SCS)
Number of subjects: 152
Study: 26352288

Group type: EXPERIMENTAL
Intervention: Increased rigidity
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pain severity (moderate or worse)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pain interference with work
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Tremor
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Motor impairments
Number of subjects: 231
Study: 24435244

Group type: EXPERIMENTAL
Intervention: 30mg Oramorph® (morphine sulphate)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 21901396

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and 5-azacytidine 75 mg/m2 daily on days 1-4 and 15-18 of a 28-day cycle
Number of subjects: 30
Study: 18369376

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pascal dynamic contour tonometer (PDCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both GAT and PDCT
Number of subjects: 100
Study: 17309589

Group type: EXPERIMENTAL
Intervention: 7.5% povidone-iodine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study: 15371784

Group type: EXPERIMENTAL
Intervention: Body temperature (BT) saline
Number of subjects: 91

Group type: COMPARATOR
Intervention: Room temperature (RT) saline
Number of subjects: 91
Study: 11856085

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 240

Group type: COMPARATOR
Intervention: Butyl scopolamine bromide (SC group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Glucagon (in complicated patients, GC group)
Number of subjects: 240
Study: 9951595

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus mometasone furoate
Number of subjects: 20
Study: 7788232

Group type: EXPERIMENTAL
Intervention: Ultrasound transmission velocity (UTV) measurement
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurement
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis for UTV
Number of subjects: 313
Study: 2170893

Group type: EXPERIMENTAL
Intervention: medium flavoring with medium tartar control (toothpaste B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: high flavoring with medium tartar control (toothpaste C)
Number of subjects: 92

Group type: COMPARATOR
Intervention: control‐low flavor with no tartar control (toothpaste A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: medium flavoring with no tartar control (toothpaste D)
Number of subjects: 92
Study: 103190

Group type: EXPERIMENTAL
Intervention: D‐penicillamine (600 mg daily for one year)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gold (sodium aurothiomalate 50 mg weekly up to a total of 13 mg/kg, then 50 mg once a month for one year)
Number of subjects: 100
Study: 28922213

Group type: EXPERIMENTAL
Intervention: Elastic resistance using a load cell (LC) that displays force during exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elastic resistance only
Number of subjects: 0
Study: 29237906

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy group (NRG) - 2000-3000 cGy 192 Ir irradiation of preoperatively intracavitary brachytherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgery alone group (SAG)
Number of subjects: 78
Study: 25463545

Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin (1.5 g/kg on day 1 and 1g/kg on day 3)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Antibiotics alone (control group)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin
Number of subjects: 193
Study: 23572482

Group type: EXPERIMENTAL
Intervention: Active screening (study staff screened using culture and commercial PCR)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Active screening (first PCR)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Passive screening (nonintervention arm; observation with local standard of care)
Number of subjects: 607
Study: 21327673

Group type: EXPERIMENTAL
Intervention: Propiverine ER 30 mg o.d. as monotherapy (MT)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Propiverine ER 30 mg o.d. as add-on to α-blockers (CT)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Propiverine ER treatment
Number of subjects: 1849
Study: 19617815

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) treatment with antiretroviral therapy (nucleoside analogues) for 12 months
Number of subjects: 97

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone for 12 months
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: IL-2 experienced adults on highly active antiretroviral therapy
Number of subjects: 97
Study: 15740555

Group type: EXPERIMENTAL
Intervention: EC‐MPS 640 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EC‐MPS 720 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: MMF 1000 mg
Number of subjects: 24
Study: 10321417

Group type: EXPERIMENTAL
Intervention: Acetaminophen, aspirin, and caffeine (AAC)
Number of subjects: 1220
Study: 8597320

Group type: EXPERIMENTAL
Intervention: Resistance training program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 24
Study: 1820903

Group type: EXPERIMENTAL
Intervention: New Levothyroxine solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference L-thyroxine solution
Number of subjects: 12
Study: 7042486

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Caved-S (six tablets daily)
Number of subjects: 100
Study: 31939235

Group type: EXPERIMENTAL
Intervention: Micro-fracture therapy combined with intra-articular injection of PRP
Number of subjects: 43

Group type: COMPARATOR
Intervention: Micro-fracture therapy
Number of subjects: 43
Study: 31032717

Group type: EXPERIMENTAL
Intervention: BTX-mCIMT
Number of subjects: 64

Group type: COMPARATOR
Intervention: BTX-ICT
Number of subjects: 64
Study: 29273337

Group type: EXPERIMENTAL
Intervention: QR evaluations
Number of subjects: 161
Study: 26803236

Group type: EXPERIMENTAL
Intervention: 6 months DAPT
Number of subjects: 429

Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 429
Study: 23779051

Group type: EXPERIMENTAL
Intervention: 5 nights of 4h sleep
Number of subjects: 25

Group type: COMPARATOR
Intervention: 5 nights of 9h sleep
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 nights of restricted sleep (4h)
Number of subjects: 25
Study: 22584491

Group type: EXPERIMENTAL
Intervention: Mg Pidolate (MgP) 3.0 g/day for 30 days (equivalent to 260 mg of Mg element)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60
Study: 19161949

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 50
Study: 17445650

Group type: EXPERIMENTAL
Intervention: 5-ALA fluorescence diagnosis (FD)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Conventional white light (WL)
Number of subjects: 301
Study: 15625713

Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Health promotion intervention (Control)
Number of subjects: 62
Study: 12154424

Group type: EXPERIMENTAL
Intervention: Bronchial blocker (BB) with single-lumen tube (SLT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Double-lumen tube (DLT)
Number of subjects: 159
Study: 9495267

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (antihypertensive drug treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 7658498

Group type: EXPERIMENTAL
Intervention: Tamoxifen (specific dosage and duration not mentioned)
Number of subjects: 9749
Study: 29628151

Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 3

Group type: COMPARATOR
Intervention: HBsAg-Eng
Number of subjects: 3
Study: 28568112

Group type: EXPERIMENTAL
Intervention: Early extubation (≤ 24 h) after superior cavopulmonary connection
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Factors associated with early extubation
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Alternative analyses for early extubation
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for > 24 h
Number of subjects: 390
Study: 26535958

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy (wCBT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Attention-control group (ACG)
Number of subjects: 199
Study: 23141637

Group type: EXPERIMENTAL
Intervention: ACLR knees during walking, stair ascent, and stair descent
Number of subjects: 90

Group type: COMPARATOR
Intervention: Contralateral knees during walking, stair ascent, and stair descent
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy control knees during walking, stair ascent, and stair descent
Number of subjects: 90
Study: 21199922

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 11
Study: 19181729

Group type: EXPERIMENTAL
Intervention: Breastfeeding groups intervention
Number of subjects: 18858

Group type: COMPARATOR
Intervention: Control localities (no change in group activity)
Number of subjects: 18858

Group type: EXPERIMENTAL
Intervention: Localities not participating in the trial
Number of subjects: 18858
Study: 18175665

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 30
Study: 15023106

Group type: EXPERIMENTAL
Intervention: Patient-determined leaflet
Number of subjects: 225

Group type: COMPARATOR
Intervention: Routine pre-operative information (Control)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pre-operative interview by a trained nurse
Number of subjects: 225
Study: 11453445

Group type: EXPERIMENTAL
Intervention: Multisensory (auditory‐tactile‐visual‐vestibular) intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 9669812

Group type: EXPERIMENTAL
Intervention: Fluconazole in addition to standard prophylaxis (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard prophylaxis only (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Number of subjects: 68
Study: 7846918

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 100
Study: 3348155

Group type: EXPERIMENTAL
Intervention: Dannon yogurt
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Royal Maid yogurt
Number of subjects: 8

Group type: COMPARATOR
Intervention: Borden yogurt
Number of subjects: 8
Study: 31805311

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 0
Study: 30447012

Group type: EXPERIMENTAL
Intervention: Online serious game for dental treatment preparation
Number of subjects: 60
Study: 28205033

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 200
Study: 26480199

Group type: EXPERIMENTAL
Intervention: CB group
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 631

Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 631
Study: 23320444

Group type: EXPERIMENTAL
Intervention: To-be-remembered words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: To-be-forgotten words
Number of subjects: 0
Study: 20945066

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 115
Study: 19114188

Group type: EXPERIMENTAL
Intervention: Moderate-potassium adenosine-lidocaine (MPAL) group (K(+), 10 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Moderate-potassium adenosine-lidocaine (MPAL) group
Number of subjects: 134

Group type: COMPARATOR
Intervention: High-potassium (HP) group (K(+), 20 mmol/L)
Number of subjects: 134

Group type: COMPARATOR
Intervention: High-potassium adenosine-lidocaine (HPAL) group (K(+), 20 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Number of subjects: 134
Study: 16543907

Group type: EXPERIMENTAL
Intervention: GW660511X 200 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 12941708

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily for 3 months)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 136
Study: 11326696

Group type: EXPERIMENTAL
Intervention: Irinotecan alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Irinotecan in combination with oxaliplatin and high dose 5-FU/FA
Number of subjects: 17
Study: 8653990

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg tablet)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Terbinafine and terfenadine coadministration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Terbinafine placebo
Number of subjects: 26
Study: 1451313

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (PI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: standardized 10% povidone-iodine (SPI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: reformulated standardized 10% povidone-iodine (RSPI)
Number of subjects: 12
Study: 6374681

Group type: EXPERIMENTAL
Intervention: Trazodone administered as a single dose at night
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Trazodone administered as divided doses twice daily
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both treatment groups (single dose at night and divided doses)
Number of subjects: 146
Study: 31708330

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 147

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study: 29146196

Group type: EXPERIMENTAL
Intervention: MRI-based splint thickness in subgroup IB (disk displacement with reduction)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: MRI-based splint thickness in subgroup IIB (disk displacement without reduction)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 3-mm-thick splints in subgroup IA (disk displacement with reduction)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 3-mm-thick splints in subgroup IIA (disk displacement without reduction)
Number of subjects: 162
Study: 27050245

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 12
Study: 24594552

Group type: EXPERIMENTAL
Intervention: Serelaxin, a recombinant form of human relaxin‐2
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Non-RELAX‐AHF‐type patients
Number of subjects: 1161
Study: 22001114

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphonylurea (Glipizide) + Metformin
Number of subjects: 0
Study: 19875266

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional face-to-face counseling about child's fasting
Number of subjects: 124

Group type: COMPARATOR
Intervention: Current information without face-to-face counseling
Number of subjects: 124
Study: 18047611

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen cryosurgery alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Combination of liquid nitrogen cryosurgery and intralesional triamcinolone acetonide
Number of subjects: 21
Study: 15025908

Group type: EXPERIMENTAL
Intervention: Rational belief that disagreement is not destructive
Number of subjects: 150

Group type: COMPARATOR
Intervention: Irrational belief that disagreement is destructive
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control condition (counter-demand instructions)
Number of subjects: 150
Study: 11424462

Group type: EXPERIMENTAL
Intervention: Conscious sedation by propofol (Group P)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No sedation (Group C)
Number of subjects: 28
Study: 9731006

Group type: EXPERIMENTAL
Intervention: Theophylline (mean serum level: 9.9 +/- 1.1 mg/L, Days 1 to 40) + inhaled salmeterol (50 microgram twice daily, Days 8 to 36)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo + inhaled salmeterol (50 microgram twice daily, Days 8 to 36)
Number of subjects: 25
Study: 8067245

Group type: EXPERIMENTAL
Intervention: Oxymetazoline administered with a nasal bellows (OXBE)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo bellows (PLBE)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oxymetazoline with conventional nasal spray (OXSP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo nasal spray (PLSP)
Number of subjects: 121
Study: 2493760

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31486407

Group type: EXPERIMENTAL
Intervention: MotiMate app (full version)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control app (monitoring only)
Number of subjects: 88
Study: 28711476

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27325390

Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon 0.3 µg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon 1.2 µg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon 2.0 µg/kg
Number of subjects: 19

Group type: COMPARATOR
Intervention: GlucaGen 2.0 µg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon
Number of subjects: 19
Study: 24534400

Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone 400 μg twice daily for 10 days
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone 400 μg
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 525
Study: 22076554

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling during a 12 months intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling
Number of subjects: 0
Study: 20308971

Group type: EXPERIMENTAL
Intervention: Circuit-High Intensity Group (CHG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Circuit-Low Intensity Group (CLG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endurance Group (EG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 17549472

Group type: EXPERIMENTAL
Intervention: TIL plus interleukin-2 (IL-2) for 2 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: IL-2 only
Number of subjects: 88
Study: 15995044

Group type: EXPERIMENTAL
Intervention: Chronic myelogenous leukemia (CML) in children and adolescents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symptoms related to splenomegaly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: b3a2 transcript presence
Number of subjects: 40
Study: 12518668

Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg/day) followed by tamsulosin (0.4 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/day) followed by terazosin (5 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cross-over treatment (terazosin followed by tamsulosin and vice versa)
Number of subjects: 60
Study: 10432468

Group type: EXPERIMENTAL
Intervention: 100 mg D-cycloserine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0